Perlegen, Lilly Expand Pharmacogenomics Research Collaboration | GenomeWeb

NEW YORK, Sept. 23 (GenomeWeb News) - Perlegen Sciences said that Eli Lilly will increase its funding in support of the companies' ongoing pharmacogenomics research collaboration.

Under the partnership, which was struck in Dec. 2002, Perlegen is using its proprietary technology to genotype SNPs in clinical samples and discover genetic markers for Lilly.

Perlegen said that the increased funding is in addition to milestones and payments Lilly is making under the original deal.

Specific terms of the arrangement remain undisclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.